Skip to content
Bored Studies
RecruitingPhase 2

A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder

Alkermes, Inc. · NCT07901179

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
180
US sites recruiting
1
Study start
October 2026
Record last updated
October 28, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to assess the efficacy, safety and tolerability of ALKS 7290 following oral administration in adult participants with Major Depressive Disorder.

Being studied: ALKS 7290 Dose; Placebo

Conditions: Major Depressive Disorder (MDD)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Meets the DSM-5 criteria for MDD, as confirmed by both MINI and an adequate clinical psychiatric evaluation.
  • Is otherwise healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring.
  • Participants must be stable on permitted medication prior to screening.
  • An inadequate response to an adequate dosage of antidepressant therapy in the current depressive episode.
  • Symptoms of depression that are considered moderate to severe, based on assessments completed with the study team during both screening and baseline visits.
  • Has a BMI within 18 to 35 kg/m2 at Screening

Exclusion Criteria

  • Diagnosis of schizophrenia, schizoaffective disorder, or bipolar I or II disorder, moderate to severe substance use disorder
  • Significant problems with memory, thinking, learning or understanding that could make it difficult to complete study activities or follow study instructions. This includes conditions such as dementia or other disorders affecting thinking and memory that have been present within the past two years.
  • Participant poses a current suicide risk as assessed by the Investigator or as confirmed by the C-SSRS
  • Any other psychiatric condition that could interfere with participation in the study.

Recruiting US locations

Study contacts (from the official record)

  • Director, Clinical Trial Manager · 888-235-8008 (US Only) · clinicaltrials@alkermes.com
  • Director, Clinical Trial Manager · 571-599-2702 (Global) · clinicaltrials@alkermes.com
All sleep studies in Florida →
A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an… (NCT07901179) | Bored Studies